Boc-beta-cyclohexyl-L-alaninol

Boc-beta-cyclohexyl-L-alaninol is a Boc-protected amino alcohol derivative built on an L-alaninol scaffold with a beta-cyclohexyl substituent, providing a stereodefined, conformationally biased side chain. This protected amino alcohol format is commonly used as a chiral building block in medicinal chemistry and peptide-mimetic synthesis, where controlled functional-group presentation is required for downstream coupling and stereochemical integrity. The Boc carbamate also makes the compound practical for multi-step intermediate workflows that tolerate standard organic synthesis conditions.

1. Peptidomimetic Building Blocks

Boc-beta-cyclohexyl-L-alaninol is frequently used in peptidomimetic and constrained amino alcohol design, where the alaninol motif serves as a key stereochemical and hydrogen-bonding element while the beta-cyclohexyl group can impose hydrophobic and conformational effects. Research groups developing non-peptide backbones or side-chain-modified analogs rely on this Boc-protected amino alcohol to introduce a defined chiral center into larger fragments without premature reactivity. The protected amine functionality supports sequential assembly strategies typical of medicinal chemistry programs, including late-stage fragment coupling to generate analog libraries for structure-activity relationship studies.

2. Pharmaceutical Intermediate Synthesis

Boc-beta-cyclohexyl-L-alaninol is also used as a chiral pharmaceutical intermediate for constructing more complex nitrogen-containing scaffolds that retain the amino alcohol functionality for further derivatization. Process and synthesis teams value the Boc protection because it provides a stable handle during the formation of adjacent bonds and functional group interconversions, while keeping the amino alcohol poised for downstream transformations. This compound is particularly relevant when a beta-substituted alaninol unit is required as a stereodefined building block for drug-discovery chemistry, including the preparation of analogs and advanced intermediates used in custom synthesis workflows.

3. Chiral Fragment Coupling

Boc-beta-cyclohexyl-L-alaninol supports stereochemically controlled fragment coupling in solution-phase synthesis, especially when the target structure requires an amino alcohol-bearing stereocenter to be carried through multiple steps. Medicinal chemistry and chemical biology synthesis groups often select Boc-protected amino alcohols to manage chemoselectivity during assembly of larger molecules, using the protected amine to avoid side reactions while the alcohol and substituted backbone remain available for planned derivatization. The beta-cyclohexyl substituent further contributes to the distinct steric environment of the fragment, which can be advantageous when building bulky, conformationally restricted motifs.

4. Stereodefined Amine Derivatization

Boc-beta-cyclohexyl-L-alaninol is used as a stereodefined precursor for generating downstream amino alcohol derivatives, including protected or activated forms that require retention of the L-configuration during functional group programming. Synthetic chemists incorporate this type of Boc-protected amino alcohol when they need a reliable starting point for converting the alcohol and/or unmasking the amine in a controlled manner as part of multi-step derivatization sequences. In research settings focused on building libraries of chiral intermediates, the Boc-protected format helps standardize handling and improves reproducibility across parallel synthesis campaigns.

1. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore

2. Quantitative Analysis of Ligands Effects on Bioefficacy of Nanoemulsion encapsulating Depigmenting Active

3. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

4. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

5. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis